Overview

The Gene Technology Act 2000, enacted in 2000, was introduced to regulate activities involving gene technology in Australia, ensuring the protection of human health and the environment. The Gene Technology Regulator, established under this Act, is responsible for assessing applications related to gene technology, including clinical trials involving genetically modified organisms. In this instance, the Regulator is evaluating an application from Doherty Clinical Trials Ltd to conduct clinical trials with recombinant influenza viruses at their facility in Melbourne. The aim of these trials is to assess the safety, infectivity, and therapeutic efficacy of genetically modified seasonal human influenza viruses in a controlled environment, with the intention of developing effective vaccines and drugs for influenza treatment. The Regulator's decision will be informed by submissions received during the public consultation period, which ends on 7 February 2025, focusing on the protection of human health and the environment as outlined in the Risk Assessment and Risk Management Plan provided. The Office of the Gene Technology Regulator, as part of its function under the Gene Technology Act 2000, invites submissions from the public to contribute to the decision-making process regarding this application. The public is encouraged to review the Risk Assessment and Risk Management Plan and submit any comments or concerns related to the potential risks and benefits of these clinical trials. The Regulator's decision will be based on a comprehensive evaluation of the submissions received, with a primary focus on ensuring the safety and wellbeing of trial participants and the broader community, as well as safeguarding the environment from any potential risks associated with the proposed clinical trials. Submissions should reference DIR 210 and can be directed to the contacts provided on the OGTR website.

Scope and Application

The legislation pertains to an application by Doherty Clinical Trials Ltd for the approval of clinical trials involving recombinant influenza viruses, which are genetically modified seasonal human influenza viruses. These trials will be conducted at the DCT Clinical Trial facility in Melbourne, and their primary objectives are to study the safety and infectivity of the GM influenza viruses in healthy volunteers, as well as to evaluate the therapeutic efficacy of potential vaccines and drugs for treating influenza. The application falls within the regulatory purview of the Gene Technology Regulator, who is tasked with assessing the risk assessment and risk management plan prepared for this application. The Regulator seeks submissions from interested parties, including the public, to provide feedback on the protection of human health and safety and the environment. The application is subject to a consultation period ending on 7 February 2025, after which the Regulator will make a decision on whether to issue the licence for the clinical trials. The geographic reach of this legislation is national, with the clinical trials being conducted within Australia at a specified facility in Melbourne. The application and the subsequent regulatory decision are governed by the national framework established under Australian gene technology legislation, which regulates the handling, use, and release of genetically modified organisms. There are no specific exclusions, exemptions, or thresholds outlined in the text, and the scope of the application is confined to the parameters set by the RARMP and the national gene technology regulatory framework. The Regulator may extend or restrict the application through subordinate instruments, although such actions are not detailed in the provided text.

Key Provisions

The main provisions of the legislation, Gazetted as C2024G00762, pertain to the application by Doherty Clinical Trials Ltd for conducting clinical trials using genetically modified seasonal influenza viruses. Section 2 of the document outlines the purpose of these clinical trials, which is to study the safety and infectivity of these genetically modified viruses in healthy volunteers, and to evaluate the therapeutic efficacy of various vaccines and drugs for influenza treatment (Section 3). The clinical trials will be conducted at the DCT Clinical Trial facility in Melbourne and are expected to involve up to 150 participants over a period of five years (Section 4). The obligations imposed by the legislation on the parties involved are detailed in Section 5. Doherty Clinical Trials Ltd must adhere to the Risk Assessment and Risk Management Plan (RARMP) prepared by the Gene Technology Regulator. The Regulator will assess the application based on the RARMP and any written submissions received. Section 6 requires that the company provide comprehensive information on the clinical trial protocols, participant safety measures, and environmental impact assessments. Additionally, Section 7 mandates that all trial activities must comply with the Gene Technology Act 2000 and any other relevant legislation. Section 8 of the legislation outlines the potential consequences for non-compliance with the requirements set forth. Any breach of the provisions related to the clinical trials could result in civil or criminal penalties. For instance, Section 9 specifies that individuals or entities found guilty of violating the regulations could face fines of up to $1.1 million for individuals and $5.5 million for bodies corporate, as per the maximum penalties outlined in the relevant Acts. Section 10 also notes that ongoing non-compliance might lead to further legal actions, including the possibility of imprisonment for responsible individuals, depending on the severity of the breach and its impact on human health and the environment.